Walleye Capital LLC Takes $5.31 Million Position in Zenas BioPharma, Inc. $ZBIO

Key Points

• Walleye Capital acquired 209,050 shares of Zenas BioPharma valued at approximately $5.31 million, representing about 0.33% of the company; several other institutional investors also increased their positions.
• Analyst sentiment is mixed but leans positive, with six Buy, two Hold, and one Sell rating, producing a consensus “Moderate Buy” rating and an average price target of $45.71. CEO Leon O. Moulder Jr. also purchased 60,000 shares for roughly $1.01 million.
• Zenas reported a quarterly loss of $1.77 per share versus the $1.12 consensus estimate, while revenue of $1 million fell well short of expectations of $15 million. The stock opened at $29.51, compared with a 52-week range of $13.50 to $44.60.

Walleye Capital LLC acquired a new stake in Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report) in the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 209,050 shares of the company's stock, valued at approximately $5,306,000. Walleye Capital LLC owned approximately 0.33% of Zenas BioPharma as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in ZBIO. Quarry LP lifted its holdings in Zenas BioPharma by 34.5% during the third quarter. Quarry LP now owns 1,134 shares of the company's stock worth $25,000 after acquiring an additional 291 shares in the last quarter. Deutsche Bank AG grew its stake in Zenas BioPharma by 4.5% in the fourth quarter. Deutsche Bank AG now owns 12,781 shares of the company's stock valued at $464,000 after acquiring an additional 554 shares during the period. CWM LLC increased its holdings in shares of Zenas BioPharma by 48.3% in the fourth quarter. CWM LLC now owns 2,178 shares of the company's stock worth $79,000 after acquiring an additional 709 shares in the last quarter. Two Sigma Investments LP increased its holdings in shares of Zenas BioPharma by 3.9% in the third quarter. Two Sigma Investments LP now owns 20,382 shares of the company's stock worth $452,000 after acquiring an additional 765 shares in the last quarter. Finally, Bank of America Corp DE raised its position in shares of Zenas BioPharma by 5.8% during the third quarter. Bank of America Corp DE now owns 14,809 shares of the company's stock worth $329,000 after purchasing an additional 818 shares during the period.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ZBIO shares. Zacks Research upgraded Zenas BioPharma from a "strong sell" rating to a "hold" rating in a report on Friday, May 15th. Wall Street Zen raised Zenas BioPharma from a "strong sell" rating to a "sell" rating in a research note on Saturday, June 27th. Weiss Ratings cut Zenas BioPharma from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Thursday, July 9th. Citigroup restated a "buy" rating on shares of Zenas BioPharma in a report on Wednesday, June 3rd. Finally, Guggenheim reaffirmed a "buy" rating and issued a $55.00 price target on shares of Zenas BioPharma in a research note on Friday. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $45.71.

Insider Activity

In other news, CEO Leon O. Moulder, Jr. bought 60,000 shares of the company's stock in a transaction that occurred on Monday, May 18th. The shares were acquired at an average price of $16.88 per share, with a total value of $1,012,800.00. Following the transaction, the chief executive officer owned 96,928 shares in the company, valued at $1,636,144.64. This represents a 162.48% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 22.00% of the company's stock.

Zenas BioPharma Price Performance

ZBIO stock opened at $29.51 on Friday. The stock has a 50-day moving average price of $26.95 and a two-hundred day moving average price of $23.38. The stock has a market cap of $1.86 billion, a PE ratio of -3.28 and a beta of -1.03. The company has a current ratio of 11.94, a quick ratio of 11.94 and a debt-to-equity ratio of 1.04. Zenas BioPharma, Inc. has a 1 year low of $13.50 and a 1 year high of $44.60.

Zenas BioPharma (NASDAQ:ZBIO - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($1.77) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.65). The business had revenue of $1.00 million during the quarter, compared to analysts' expectations of $15.00 million. Equities analysts forecast that Zenas BioPharma, Inc. will post -4.47 EPS for the current fiscal year.

About Zenas BioPharma

Zenas BioPharma, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel therapies in oncology and infectious diseases. The company's proprietary platform integrates structure-guided design, computational modeling and high-throughput screening to address challenging protein-protein interactions. Zenas BioPharma is advancing multiple preclinical and clinical-stage candidates aimed at providing new treatment options where current modalities may be limited by efficacy or safety concerns.

Founded in 2021 and headquartered in Cambridge, Massachusetts, Zenas BioPharma was built to streamline the drug discovery process from target identification through to IND-enabling studies.

Want to see what other hedge funds are holding ZBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zenas BioPharma, Inc. (NASDAQ:ZBIO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source